{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:36:23Z","timestamp":1790818583283,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T00:00:00Z","timestamp":1501891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T00:00:00Z","timestamp":1501891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"No sources of funding were used to conduct this study or prepare this manuscript"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40264-017-0581-7","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T07:16:48Z","timestamp":1501917408000},"page":"1279-1292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-9578","authenticated-orcid":false,"given":"Rachel B.","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse A.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Matcho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Schuemie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Swerdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,5]]},"reference":[{"key":"581_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0272-6386(03)00647-4","volume":"42","author":"T Kurth","year":"2003","unstructured":"Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003;42:234\u201344.","journal-title":"Am J Kidney Dis"},{"key":"581_CR2","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1001\/archinte.162.19.2204","volume":"162","author":"GC Curhan","year":"2002","unstructured":"Curhan GC, Willett WC, Rosner B, et al. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204\u20138.","journal-title":"Arch Intern Med"},{"key":"581_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.HYP.0000035856.77718.DA","volume":"40","author":"J Dedier","year":"2002","unstructured":"Dedier J, Stampfer M, Hankinson S, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604\u20138.","journal-title":"Hypertension"},{"key":"581_CR4","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.105.595793","volume":"113","author":"AT Chan","year":"2006","unstructured":"Chan AT, Manson JE, Albert CM, et al. Nonsteroidal anti-inflammatory drugs, paracetamol, and the risk of cardiovascular events. Circulation. 2006;113:1578\u201387.","journal-title":"Circulation"},{"key":"581_CR5","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/ndt\/gfn745","volume":"24","author":"M Evans","year":"2009","unstructured":"Evans M, Fored CM, Bellocco R, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant. 2009;24:1908\u201318.","journal-title":"Nephrol Dial Transplant"},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0895-4356(03)00152-5","volume":"56","author":"L Lipworth","year":"2003","unstructured":"Lipworth L, Friis S, Mellemkjaer L, et al. A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. J Clin Epidemiol. 2003;56:796\u2013801.","journal-title":"J Clin Epidemiol"},{"key":"581_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2125.2010.03705.x","volume":"70","author":"F de Vries","year":"2010","unstructured":"de Vries F, Setakis E, van Staa TP, et al. Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. Br J Clin Pharmacol. 2010;70:429\u201338.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"581_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/annrheumdis-2014-206914","volume":"75","author":"E Roberts","year":"2016","unstructured":"Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, Doherty M, Zhang W, Birrell F, Porcheret M, Dziedzic K, Bernstein I, Wise E, Conaghan PG. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75(3):552\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"581_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herret","year":"2015","unstructured":"Herret E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"key":"581_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s40264-014-0214-3","volume":"37","author":"A Matcho","year":"2014","unstructured":"Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a Clinical Practice Research Datalink conversion to the OMOP common data model. Drug Saf. 2014;37:945\u201359.","journal-title":"Drug Saf"},{"issue":"1","key":"581_CR11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc B. 1996;58(1):267\u201388.","journal-title":"J R Stat Soc B"},{"issue":"3","key":"581_CR12","first-page":"11","volume":"2013","author":"AM Walker","year":"2013","unstructured":"Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S. A tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res. 2013;2013(3):11\u201320.","journal-title":"Comp Eff Res."},{"key":"581_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jclinepi.2014.12.014","volume":"68","author":"PC Austin","year":"2015","unstructured":"Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol. 2015;68:627\u201336.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 1","key":"581_CR14","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s40264-013-0097-8","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33\u201347. doi: 10.1007\/s40264-013-0097-8 .","journal-title":"Drug Saf."},{"key":"581_CR15","volume-title":"Drug-induced diseases: prevention, detection, and management","author":"JE Tisdale","year":"2010","unstructured":"Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. Bethesda: American Society of Health-System Pharmacists; 2010."},{"issue":"2","key":"581_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/sim.5925","volume":"33","author":"MJ Schuemie","year":"2014","unstructured":"Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209\u201318.","journal-title":"Stat Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0581-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:44:02Z","timestamp":1719362642000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0581-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,5]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0581-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,5]]},"assertion":[{"value":"5 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript. Janssen Research and Development is the sponsor of Open Access.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jesse A. Berlin, Daniel Fife, Amy Matcho, Kayur Patel, Martijn Schuemie, Joel Swerdel, Patrick Ryan, and Rachel Weinstein were full-time employees of Johnson & Johnson, or a subsidiary, at the time the study was conducted. Johnson & Johnson manufactures several medications that contain paracetamol or ibuprofen. Jesse A. Berlin, Daniel Fife, Amy Matcho, Kayur Patel, Martijn Schuemie, Joel Swerdel, Patrick Ryan, and Rachel Weinstein own stock, stock options and pension rights from the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study is based on data from the CPRD obtained under license from the UK Medicines and Healthcare products RegulatoryAgency. The protocol for this study is available at ClinicalTrials.gov (NCT identifier: NCT02830178) and was approved by the data provider\u2019s ISAC (protocol 15_173R).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}